Sugi Predict

Sugi Predict / Compounds / SCHEMBL2553699

SCHEMBL2553699

SCHEMBL2553699

Nc1cc2c(Br)ccc(Cl)c2cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ KMO O15229 1/20 0.35
▸ PDPK1 O15530 1/20 0.34
▸ AXL P30530 1/20 0.34
▸ GRM1 Q13255 1/20 0.34
▸ MPO P05164 1/20 0.33
▸ TPO P07202 1/20 0.33
▸ EPX P11678 1/20 0.33
▸ LPO P22079 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ PIK3CD O00329 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ APAF1 O14727 1/20 0.33
▸ TDP2 O95551 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30224855 1.00 EGFR (0.36) EGFRDYRK1AKMOPDPK1AXL
SCHEMBL2554285 0.93 EGFR (0.36) EGFRDYRK1AKMOPDPK1AXL
SCHEMBL23649830 0.81 CSNK2A1 (0.43) EGFRDYRK1A
SCHEMBL30040948 0.81 CSNK2A1 (0.43) EGFRDYRK1A
SCHEMBL2551647 0.78 NOS3 (0.45) EGFRPDPK1AXLALOX5APFEN1
SCHEMBL2549812 0.75 GRM1 (0.35) EGFRGRM1ALOX5APFEN1NOS3
SCHEMBL15460042 0.74 NOS3 (0.45) EGFRPDPK1AXLALOX5APFEN1
SCHEMBL31426287 0.74 NOS3 (0.45) EGFRPDPK1AXLALOX5APFEN1
SCHEMBL559510 0.74 ALOX5AP (0.39) EGFRPDPK1AXLGRM1ALOX5AP
SCHEMBL2554129 0.74 ALOX5AP (0.42) EGFRDYRK1AALOX5APFEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279771-B MAP4K1 inhibitors 缆图药品公司 2025-03-21 — — CN disclosed
US-12042495-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-07-23 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-11534441-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2022-12-27 — — US disclosed
EP-4090663-A1 MAP4K1 INHIBITORS Blueprint Medicines Corporation (US) 2022-11-23 — — EP disclosed
CN-115279771-A MAP4K1 inhibitors 缆图药品公司 2022-11-01 — — CN disclosed
US-20220323438-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2022-10-13 — — US disclosed
WO-2021146370-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2021-07-22 — — WO disclosed
WO-2021146370-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2021-07-22 — — WO disclosed
US-8889676-B2 3-ureidoisoquinolin-8-yl derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2014-11-18 — — US disclosed
US-8889676-B2 3-ureidoisoquinolin-8-yl derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2014-11-18 — — US disclosed
EP-2552893-B1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-10-29 — — EP disclosed
US-20140038961-A1 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2014-02-06 — — US disclosed
US-20140038961-A1 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2014-02-06 — — US disclosed
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives BUR DANIEL (CH) 2013-04-18 — — US disclosed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 — — EP disclosed
WO-2012131588-A1 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-10-04 — — WO disclosed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11534441-B2 MAP4K1 inhibitors MAP4K1, MAP4K4, MAP4K2 EGFR 1335/4885DYRK1A 530/4885KMO 3467/4885
US-20220323438-A1 MAP4K1 INHIBITORS MAP4K1, MAP4K4, MAP4K2 EGFR 1335/4885DYRK1A 530/4885KMO 3467/4885
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives CLIC1, IRF3, KCNH3 EGFR 2150/4885DYRK1A 2256/4885KMO 3306/4885
US-20230140954-A1 MAP4K1 INHIBITORS MAP4K1, MAP4K4, MAP4K2 EGFR 1335/4885DYRK1A 530/4885KMO 3467/4885
US-12042495-B2 MAP4K1 inhibitors MAP4K1, MAP4K4, MAP4K2 EGFR 1335/4885DYRK1A 530/4885KMO 3467/4885
US-20140038961-A1 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES CBR3, CBR1, REL EGFR 1660/4885DYRK1A 915/4885KMO 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.